Although the use of vasodilator therapy in sepsis is debated (6, 32, 33), a reduction of circulating ET-1 levels through a combined ETA/ETB receptor-targeted treatment regimen has been demonstrated to ameliorate microcirculatory deficit in sepsis (17). The gene discussed is EDNRA; the disease is Sepsis.